Related Experiment Video
Updated: Jul 3, 2026

Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
Lamivudine-induced red cell aplasia.
Melanie-Anne A John1, Yasin A Rhemtula2, Colin N Menezes2,1
1Infectious Diseases Unit, Division of Clinical Microbiology and Infectious Diseases, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Lamivudine can cause pure red cell aplasia (PRCA), a rare but serious anemia in HIV patients. Stopping lamivudine (3TC) treatment led to rapid recovery in a documented case.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Background:
- Anemia is common in Human Immunodeficiency Virus (HIV) patients, with antiretroviral drugs often implicated.
- While zidovudine is a known cause of anemia, lamivudine-associated pure red cell aplasia (PRCA) is less recognized.
Observation:
- A case of lamivudine-induced PRCA is presented in an HIV-infected patient.
- The patient required significant blood transfusions before treatment withdrawal.
Findings:
- Lamivudine (3TC) cessation resulted in swift recovery from PRCA.
- The onset of lamivudine-induced PRCA is variable and not dependent on CD4(+) count.
Implications:
- This case highlights the infrequent but serious risk of lamivudine-induced PRCA.
- Awareness and prompt drug withdrawal are crucial for managing this condition.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cytomegalovirus Disease
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Antiviral Nucleoside Inhibitors
Drug toxicity: Idiosyncratic Reactions